HEALTHTECH SECURITY
KORU Medical | October 13, 2022
KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates.
“We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.”
Linda Tharby, President and CEO
Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology.
“I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.”
About KORU Medical
KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.
Read More
HEALTHTECH SECURITY
BeeKeeperAI and Novartis Biome | October 20, 2022
BeeKeeperAI, the pioneer in sightless computing on protected data, announced that it worked with scientists from Novartis Biome’s Evidence Lab and the University of California, San Francisco to train and validate an algorithm to predict instances of a rare childhood condition using real patient data from health records. This project marks the first time that confidential computing technology has been leveraged to support sightless computation by an algorithm against protected health information.
“This project is an important milestone in the development of the rare disease solution by the Evidence Lab,” said Robin Roberts, Co-founder and Chief Operating Officer at Novartis Biome. “Rare diseases are often challenging to diagnose and if left untreated, they can significantly diminish a patient’s quality of life. With BeeKeeperAI, our scientists were able to securely access a large gold standard dataset that enabled us to improve the predictive capabilities of our algorithm, bringing us much closer to identifying patients early in the disease course and to improving their outcomes.”
The Novartis Biome Evidence Lab was developed in collaboration with health systems and data providers as a space for health tech companies to test their digital solutions and identify ways to optimize and scale their offerings. BeeKeeperAI’s zero trust architecture supports sightless computing of algorithms against protected information. It uses advanced encryption within secure computing enclaves to enable data stewards and algorithm developers to collaborate without exposing the data or revealing important IP. The platform eliminates reliance on data deidentification or difficult to enforce contractual agreements that typically govern access to protected health information.
“The traditional mechanisms for securing permission to use confidential patient information to develop healthcare AI are time-consuming and costly and that has slowed the pace of innovation in the field. We developed our platform with an eye towards addressing the constraints of existing approaches for accessing protected information and helping algorithm developers and data stewards collaborate far more effectively,”
Michael Blum, MD, Co-founder and Chief Executive Officer at BeeKeeperAI
The Novartis project leveraged Microsoft Azure’s confidential computing environment utilizing an Intel SGX secure enclave. Prior to moving the data into the secure enclave at UCSF, BeeKeeperAI worked with clinical and data science experts at UCSF to curate, harmonize, and encrypt data that included 28 pediatric patients diagnosed with the pediatric rare disease in question and an additional 2,000 matched controls. Simultaneously, BeeKeeperAI enabled the Novartis scientists to prepare the algorithm for the secure environment, including encrypting and uploading it to the BeeKeeperAI cloud platform. Encrypting both the data and the algorithm ensured that they remain protected throughout the computing process.
Once the encrypted algorithm and data were in the secure enclave, they were decrypted, and the algorithm was allowed to compute against the identifiable data. The process was fully automated and sightless. The output of the computation was a report that provided performance metrics. Novartis scientists used the feedback from the BeeKeeperAI platform to fine-tune the algorithm and rerun it against the data. Through this iterative loop, they significantly improved the predictive capabilities of their solution to detect patients with the rare condition. The solution is now ready for further validation at additional academic medical centers known for treating this rare condition.
BeeKeeperAI will be participating in the Novartis Biome's "Closing the Digital Divide: Validation through Partnership" event on Wednesday, October 19, where they will share more details of the healthcare AI project with Novartis Biome and UCSF.
About Novartis Biome
Novartis Biome is a bridge to help partners become an extension of Novartis own teams, working with them as easily and productively as possible to jointly innovate and co-develop digital solutions at scale. The Biome is committed to partnering with the best in the ecosystem to combine deep scientific experience with the expertise of the tech world to develop – and crucially – scale digital solutions that improve and extend patients’ lives.
About BeeKeeperAI
BeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce.
Read More
HEALTHTECH SECURITY,HEALTHCARE ANALYTICS
Health Catalyst | December 06, 2022
Health Catalyst, Inc. a leading provider of data and analytics technology and services to healthcare organizations announced an expansive, multi-year contract with Carle Health an integrated health system based in Urbana, Illinois that includes five hospitals, multi-specialty physician group practices with more than 1,000 doctors and advanced practice providers, and Health Alliance Medical Plans—deepening its relationship with Health Catalyst to further advance Carle's innovative analytics capabilities system-wide.
"Carle Health is excited to announce this novel partnership with Health Catalyst. When combined with our own clinical expertise, Health Catalyst will help us transform the way we use data to support organizational decisions and improve patient outcomes. As a transformative health care system, it's important that we lay the groundwork to ensure we're able to provide the right solutions that blend data, analytics, and medical expertise to optimize the quality of care we provide for everyone who depend on us."
Carle Health Chief Operating Officer, Matthew Kolb
Strengthening the existing relationship between Health Catalyst and Carle, this five-year agreement will include an all-access technology subscription, plus tech-enabled managed services in the areas of analytics, data management, reporting, and project management.
Beginning in January 2023, Carle Health Clinical and Business Intelligence team members will transfer employment to Health Catalyst, where they will have the opportunity to grow professionally within Health Catalyst's enhanced environment of data literacy and technology resources. As Health Catalyst employees, transitioned team members will constitute a specialized, expert team that will continue to provide analytics support and innovation to the Carle Health system.
"We're grateful to have been a partner with such a high-performing health system as Carle these past two years, contributing to its data-driven healthcare transformation efforts," said Dan Burton, CEO of Health Catalyst. "We are honored to have been chosen by Carle to continue supporting them in bringing more technology to complement and strengthen their healthcare services. Carle Health will realize greater data-informed opportunities through this partnership and we look forward to the improvements they will continue to make for their patients and the larger community."
Health Catalyst is focused on deepening and strengthening existing partnerships to help clients achieve massive, measurable healthcare improvement. Health Catalyst and Carle first entered a partnership in 2020, which enabled Carle to leverage Health Catalyst's open, scalable data platform to gain access to data and analytics solutions to measure quality and cost of care, allowing for increased and efficient sharing of analytics, and provide a comparative analytics platform to help increase learnings about costs, outcomes, and trending best practices.
Upon signing this contract expansion through 2028, Carle becomes one of Health Catalyst's largest enterprise and tech-enabled outsourcing clients, reaffirming their commitment to analytics technology that improves the quality of care delivered to patients and health plan members. Health Catalyst's expanded relationship with Carle underscores the company's compelling value proposition, significant continued commercial momentum, and the trust Health Catalyst's clients place in the company. This expansion is included in the financial guidance that Health Catalyst most recently provided during its third quarter 2022 earnings.
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its more than 500 clients leverage the cloud-based data platform or its other software applications—powered by data from over 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
About Carle Health
Carle Health combines clinical care, health insurance, research and academics in a way that solves real-world problems today with an eye toward the future. Supported by a deep philanthropic spirit, Carle is dedicated to doing what it takes to make life better for as many as possible. Its mission is to be your trusted partner in all healthcare decisions.
Based in Urbana, IL, Carle Health is an integrated system of healthcare services, which includes a five-hospital system, multi-specialty physician groups, as well as the Carle Illinois College of Medicine and the Stephens Family Clinical Research Institute.
Read More